169 related articles for article (PubMed ID: 21233829)
1. EZH2 Y641 mutations in follicular lymphoma.
Bödör C; O'Riain C; Wrench D; Matthews J; Iyengar S; Tayyib H; Calaminici M; Clear A; Iqbal S; Quentmeier H; Drexler HG; Montoto S; Lister AT; Gribben JG; Matolcsy A; Fitzgibbon J
Leukemia; 2011 Apr; 25(4):726-9. PubMed ID: 21233829
[No Abstract] [Full Text] [Related]
2. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of H3K27 methylation in cancer.
Martinez-Garcia E; Licht JD
Nat Genet; 2010 Feb; 42(2):100-1. PubMed ID: 20104248
[TBL] [Abstract][Full Text] [Related]
5. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma.
Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E
Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
[TBL] [Abstract][Full Text] [Related]
9. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states.
Wigle TJ; Knutson SK; Jin L; Kuntz KW; Pollock RM; Richon VM; Copeland RA; Scott MP
FEBS Lett; 2011 Oct; 585(19):3011-4. PubMed ID: 21856302
[TBL] [Abstract][Full Text] [Related]
10. Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder.
Hinz S; Kempkensteffen C; Christoph F; Hoffmann M; Krause H; Schrader M; Schostak M; Miller K; Weikert S
J Cancer Res Clin Oncol; 2008 Mar; 134(3):331-6. PubMed ID: 17694325
[TBL] [Abstract][Full Text] [Related]
11. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
12. Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma.
Salido M; Martinez-Avilés L; Ademà V; Ferrer A; Espinet B; Garcia M; Salar A; Besses C; Florensa L; Serrano S; Bellosillo B; Solé F
Leuk Res; 2011 Mar; 35(3):e23-4. PubMed ID: 21087793
[No Abstract] [Full Text] [Related]
13. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
[TBL] [Abstract][Full Text] [Related]
14. EZH2 mutations and their association with PICALM-MLLT10 positive acute leukaemia.
Grossmann V; Bacher U; Kohlmann A; Artusi V; Klein HU; Dugas M; Schnittger S; Alpermann T; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 May; 157(3):387-90. PubMed ID: 22235851
[No Abstract] [Full Text] [Related]
15. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Morin RD; Johnson NA; Severson TM; Mungall AJ; An J; Goya R; Paul JE; Boyle M; Woolcock BW; Kuchenbauer F; Yap D; Humphries RK; Griffith OL; Shah S; Zhu H; Kimbara M; Shashkin P; Charlot JF; Tcherpakov M; Corbett R; Tam A; Varhol R; Smailus D; Moksa M; Zhao Y; Delaney A; Qian H; Birol I; Schein J; Moore R; Holt R; Horsman DE; Connors JM; Jones S; Aparicio S; Hirst M; Gascoyne RD; Marra MA
Nat Genet; 2010 Feb; 42(2):181-5. PubMed ID: 20081860
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas.
Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H
Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774
[TBL] [Abstract][Full Text] [Related]
17. Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations.
Korfi K; Ali S; Heward JA; Fitzgibbon J
Epigenetics; 2017 May; 12(5):370-377. PubMed ID: 28106467
[TBL] [Abstract][Full Text] [Related]
18. A somatic EZH2 mutation in childhood acute myeloid leukemia.
Ernst T; Pflug A; Rinke J; Ernst J; Bierbach U; Beck JF; Hochhaus A; Gruhn B
Leukemia; 2012 Jul; 26(7):1701-3. PubMed ID: 22266912
[No Abstract] [Full Text] [Related]
19. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
Cho KS; Oh HY; Lee EJ; Hong SJ
Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
